At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
In Brief
A Phase 2 clinical trial evaluating Eribulin Mesylate and Gemcitabine Hydrochloride for Metastatic Ureter Carcinoma and 9 related conditions. Completed, enrolled 26 participants across 18 sites in 2 countries.
Detailed Summary
This phase II trial studies how well gemcitabine hydrochloride and eribulin mesylate work in treating patients with bladder cancer that has spread to other places in the body or cannot be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study Details
Timeline
Interventions
Given IV
Given IV